Loss from continuing operations before income taxes
(26,818
)
(61,390
)
(47,880
)
(42,458
)
(46,671
)
Income tax expense (benefit)
392
212
60
22
(9
)
Net loss from continuing operations
(27,210
)
(61,602
)
(47,940
)
(42,480
)
(46,662
)
Loss from discontinued operations, net of tax(2)
(1,669
)
(11,918
)
(3,560
)
(2,494
)
(5,205
)
Net loss
$
(28,879
)
$
(73,520
)
$
(51,500
)
$
(44,974
)
$
(51,867
)
Net loss per share basic and diluted:
Net loss from continuing operations per share
(0.48
)
(1.08
)
(0.86
)
(0.78
)
(0.97
)
Net loss from discontinued operations per share
(0.03
)
(0.21
)
(0.06
)
(0.05
)
(0.11
)
Weighted-average number of shares used in calculating net loss per share(3)
57,251,377
56,785,646
55,628,542
54,010,887
47,924,324
As of December 31,
(In thousands)
2016
2015
2014
2013
2012
Consolidated Balance Sheets Data:
Cash and cash equivalents
$
137,174
$
122,672
$
151,193
$
149,727
$
57,293
Short-term investments(4)
$
161,396
$
—
$
—
$
—
$
—
Working capital
$
314,263
$
125,605
$
163,900
$
155,824
$
61,650
Total assets
$
456,647
$
275,126
$
297,182
$
286,541
$
196,055
Current portion of long-term debt and capital lease obligations
$
269
$
5,519
$
3,380
$
2,637
$
14,429
Long-term debt and capital lease obligations(5)
$
332,768
$
171,967
$
166,283
$
117,627
$
101,726
Other long-term liabilities
$
5,032
$
3,952
$
2,774
$
1,943
$
1,867
Total stockholders’ equity
$
63,150
$
34,051
$
83,829
$
124,597
$
44,176
(1)
Included a charge of $6.1 million related to in-process internally developed software in 2016. See note 12 to our consolidated financial statements included in this Annual Report on Form 10-K.
(2)
Included an impairment charge of $9.0 million in 2015 related to the impairment of the Neighborhood Diabetes asset group. See note 13 to our consolidated financial statements included in this Annual Report on Form 10-K.
(3)
In January 2013, we issued and sold 4.7 million shares of common stock to the public. In July 2014, we issued 0.3 million shares of common stock in connection with the repurchase of the 3.75% Senior Convertible Notes. See note 7 to our consolidated financial statements included in this Annual Report on Form 10-K.
(4)
We invested in short-term investments beginning in 2016. See note 6 to our consolidated financial statements included in this Annual Report on Form 10-K.
(5)
In June 2008, we issued and sold $85.0 million principal amount of 5.375% Convertible Senior Notes due June 2013. In June 2011, we issued and sold $143.8 million of 3.75% Convertible Notes due June 2016 and repurchased $70 million in principal of the 5.375% Notes. In June 2014, we issued and sold $201.3 million of 2% Convertible Notes due June 2019 and repurchased $114.9 million in 3.75% Notes. In July 2014, the remaining principal balance of the 3.75% Notes were converted and the principal was settled in cash. In September 2016, we issued $345.0 million of 1.25% Convertible Notes due September 2021 and repurchased $134.2 million in principal of the 2% Notes. In 2013 and 2014 we acquired $9.0 million and $1.5 million, respectively, of manufacturing equipment under capital leases. See notes 7 and 8 to our consolidated financial statements included in this Annual Report on Form 10-K.
filings.tools